Non-Small Cell Lung Cancer Coverage from Every Angle
Advertisement
Advertisement

Recent News

ASCO20: High Risk for Hospitalization for Patients With Thoracic Malignancies and COVID-19 Infection
ASCO20: ‘Extraordinary’ Results With Adjuvant Osimertinib in Early-Stage EGFR-Mutant NSCLC
FDA Approves Chemotherapy Plus Immunotherapy Combination in First-Line Treatment of Resistant NSCLC
Pulmonology Expert Panel Offers Guidance During the COVID-19 Pandemic
FDA Approves TKI Inhibitor Brigatinib for ALK-Positive Metastatic NSCLC
COVID-19 Pandemic–Related Challenges in Lung Cancer Therapy
FDA Approves Atezolizumab for Metastatic NSCLC With High PD-L1 Expression
Nivolumab/Ipilimumab Combination Receives FDA Approval in First-Line Treatment of Metastatic NSCLC
ASCO20 Preview: Study Finds Lung Cancer Survival Improved With Even Recent Smoking Cessation
DDW 2020: Risk of Lung Cancer in Patients With Inflammatory Bowel Disease
AACR 2020: Final IMpower150 Analysis of Chemoimmunotherapy in Nonsquamous Lung Cancer
Early Phase of Lung Pathology in COVID-19: Case Studies From China
FDA Approves Selpercatinib for RET Fusion–Positive NSCLC
Capmatinib Approved by FDA for Metastatic MET Exon 14–Mutated NSCLC
AACR 2020: MET Inhibitor Therapy in Lung Cancer With Brain Metastasis
Immunotherapy-Treated Patients With Lung Cancer: Beta-Blocker and Mortality Connection?
AACR 2020: Global Registry of Mortality in Patients With Lung Cancer and COVID-19
Pembrolizumab Receives FDA Accelerated Approval for Alternative Dosing Schedule
AACR 2020: Targeting EGFR Exon 20–Mutant Non–Small Cell Lung Cancer
Lung Cancer Treatment During the COVID-19 Pandemic: Balancing Risks and Benefits
The Need for COVID-19 Testing in Patients With Lung Cancer
ESTRO/ASTRO Recommendations on Lung Cancer Radiotherapy During COVID-19 Pandemic
COVID-19 Infection in a Patient on Immunotherapy for Lung Cancer Since 2013
FDA Grants Priority Review to Nivolumab/Ipilimumab in First-Line Treatment of Lung Cancer
Predicting Sensitivity to Therapy for NSCLC With Artificial Intelligence Model
First-Line Treatment of Metastatic Lung Cancer: Patient and Caregiver Preferences
Predicting Lung Cancer Response to Immunotherapy With Multimodal Genomic Features
Pembrolizumab Plus NK-Cell Therapy for Advanced Lung Cancer
Novel Assay Is Focus of Drug Screening Research in Resistant Lung Cancer
Bispecific Antibody Granted FDA Breakthrough Therapy Designation for Exon 20–Mutated NSCLC
Can Influenza Vaccines Trigger Immune Response in Patients With Lung Cancer?
FDA Accepts Biologics License Application for Proposed Biosimilar to Bevacizumab
Physical Activity and Quality of Life After Radiation Therapy for Lung Cancer
Brigatinib Granted FDA Priority Review for ALK-Positive Metastatic NSCLC
Atezolizumab Receives FDA Priority Review in NSCLC
ASCO-SITC 2020: HLA Expression in Primary Lung Tumors and Brain Metastases
MET Inhibitor Capmatinib Granted FDA Priority Review in Advanced Lung Cancer
ASCO–SITC 2020: Interim Trial Results With Pepinemab/Avelumab in Advanced NSCLC
ASCO-SITC 2020: Radiation Recall Pneumonitis and Nivolumab for Lung Cancer
Priority Review of Selpercatinib in RET-Driven Lung Cancer Granted by FDA
STS 2020: Intraoperative Molecular Imaging During Surgery for NSCLC
Priority Review Granted by FDA to Immunotherapy Combination in Lung Cancer
PET Imaging of Mitochondrial Activity in Lung Tumor Cells
FLAURA Trial: Overall Survival With Osimertinib in EGFR-Mutated Lung Cancer
Can Skin Reactions Portend Clinical Benefit in Patients With NSCLC?
ESMO I-O 2019: Overall Survival With Nivolumab/Ipilimumab in Lung Cancer
RSNA 2019: Deep Learning Tool and Cardiovascular Health on Lung Cancer Screenings


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.